Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
Hazem Saleh Aljuhani,1,* Rahaf A Hubayni,2,3,* Jumanah Qedair,2,3 Ziad M Bukhari,4 Ahmed Alzahrani,4 Razan Osama Bawazir,2,3 Orjwan Salah Badghaish,2,3 Faisal Alqahtani5 1Ophthalmology Department, Jeddah Eye Hospital, Jeddah, Saudi Arabia; 2College of Medicine, King Saud bin...
Saved in:
| Main Authors: | Aljuhani HS, Hubayni RA, Qedair J, Bukhari ZM, Alzahrani A, Bawazir RO, Badghaish OS, Alqahtani F |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-06-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/efficacy-and-safety-of-aflibercept-biosimilars-relative-to-reference-a-peer-reviewed-fulltext-article-OPTH |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
by: Wajiha J Kheir, et al.
Published: (2025-01-01) -
Vitrectomy for full-thickness macular hole developed during aflibercept treatment for wet age-related macular degeneration
by: Agnieszka Nowosielska
Published: (2024-12-01) -
Bilateral improvement in age-related macular degeneration following unilateral Aflibercept injection
by: Muhammad Irfan Karamat, et al.
Published: (2024-12-01) -
Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2024-11-01) -
Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration
by: Bhagya Weerasinghe, et al.
Published: (2021-01-01)